Reports on the clinical benefits of CDK4/6 inhibitors such as palbociclib, ribociclib, and abemaciclib combined with fulvestrant in the second-line treatment for HR+/HER2 − advanced or metastatic breast cancer, have significantly piqued the…
Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2− advanced or metastatic breast cancer in China
